Intravenous nitroglycerin for prevention of pancreatitis after therapeutic endoscopic retrograde cholangiography: a randomized, double-blind, placebo-controlled multicenter trial

Background and study aims: Several studies have suggested that nitroglycerin promotes pancreatic drainage and thereby helps to prevent pancreatitis occurring after endoscopic retrograde cholangiography (ERC). We performed a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of intravenous nitroglycerin for preventing acute pancreatitis in moderate- to high-risk patients undergoing ERC.

Patients and methods: The patients underwent therapeutic ERC for gallstone removal, bile duct stenosis, or sphincter of Oddi dysfunction (SOD). They were randomly allocated to receive an intravenous nitroglycerin bolus of 0.1 mg, then 35 µg/kg per minute intravenously (maximum dose 9 mg) for 6 h, or an identical placebo regimen. Serum amylase and lipase levels were determined before and 24 h after ERC.

Results: The study was terminated after the interim analysis. The intention-to-treat population consisted of 208 patients enrolled in 20 centers, of whom 105 received nitroglycerin and 103 placebo therapy. Post-ERC pancreatitis (mild/moderate/severe) occurred in 25 patients, comprising 10 (3/5/2) in the nitroglycerin arm and 15 (5/6/4) in the placebo arm (OR 0.62, 95 % CI 0.26 – 1.45; P = 0.26). Pancreatitis-related hospital stays were similar in the two groups (median 4 days, range 2 – 13 days in the nitroglycerin group; median 5 days, range 2 – 20 days in the placebo group). The incidence of pancreatitis in patients with SOD did not differ between the groups (4/11 in the nitroglycerin arm, and 4/15 in the placebo arm). Adverse events were more frequent in the nitroglycerin group and led to cessation of drug infusion in 10 patients in the nitroglycerin arm and in 2 patients in the placebo arm (P = 0.019).

Conclusion: In this study, nitroglycerin offered a limited and clinically nonsignificant benefit for the prevention of post-ERC pancreatitis. Its use did not improve the technical success rate of ERC.

References

• 1 Freeman M L, Guda N M. Prevention of post-ERCP pancreatitis: a comprehensive review.  Gastrointest Endosc. 2004;  59 845-864
• 2 Singh P, Das A, Isenberg G. et al . Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials.  Gastrointest Endosc. 2004;  60 544-550
• 3 Slivka A, Chuttani R, Carr-locke D L. et al . Inhibition of sphincter of Oddi function by the nitric oxide carrier S-nitroso-N-acetylcysteine in rabbits and humans.  J Clin Invest. 1994;  94 1792-1798
• 4 Sand J, Arvola P, Jäntti V. et al . The inhibitory role of nitric oxide in the control of porcine and human sphincter of Oddi activity.  Gut. 1997;  41 375-380
• 5 Staritz M, Poralla T, Ewe K. et al . Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure.  Gut. 1985;  26 194-1977
• 6 Coelho J CU, Wiederkehr J C. Motility of Oddi’s sphincter: recent developments and clinical applications.  Am J Surg. 1996;  172 48-51
• 7 Guelrud M, Mendoza S, Rossiter G. et al . Effect of nifedipine on sphincter of Oddi motor activity: studies in healthy volunteers and patients with biliary dyskinesia.  Gastroenterology. 1988;  95 1050-1055
• 8 Khuroo M S, Zargar S A, Yattoo G N. Efficacy of nifedipine therapy in patients with sphincter of Oddi dysfunction: a prospective, double-blind, randomized, placebo-controlled, crossover trial.  Br J Clin Pharmacol. 1992;  33 477-485
• 9 Staritz M, Poralla T, Dormeyer H H. et al . Endoscopic removal of common bile duct stones through the intact papilla after medical sphincter dilation.  Gastroenterology. 1985;  88 1807-1811
• 10 Bar-Meir S, Halpern Z, Bardan E. Nitrate therapy in a patient with papillary dysfunction.  Am J Gastroenterol. 1983;  78 94-95
• 11 Tzovaras G, Rowlands B J. Diagnosis and treatment of sphincter of Oddi dysfunction.  Br J Surg. 1998;  85 588-595
• 12 Kaffes A J, Bourke M J, Ding S. et al . A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis.  Gastrointest Endosc. 2006;  64 351-357
• 13 Moreto M, Zaballa M, Casado I. et al . Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: a randomized double-blind trial.  Gastrointest Endosc. 2003;  57 1-7
• 14 Sudhindran S, Bromwich E, Edwards P R. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis.  Br J Surg. 2001;  88 1178-1182
• 15 Sherman S, Hawes R H, Troiano F P. et al . Pancreatitis following bile duct sphincter of Oddi manometry: utility of the aspirating catheter.  Gastrointest Endosc. 1992;  38 347-350
• 16 Lehman G A, Sherman S. Sphincter of Oddi dysfunction.  Int J Pancreatol. 1996;  20 11-25
• 17 Thomson I R, Mutch W AC, Culligan J D. Failure of intravenous nitroglycerin to prevent intraoperative myocardial ischemia during fentanyl-pancuronium anesthesia.  Anesthesiology. 1984;  61 385-393
• 18 Coriat P, Daloz M, Bousseau D. et al . Prevention of intraoperative myocardial ischemia during noncardiac surgery with intravenous nitroglycerin.  Anesthesiology. 1984;  61 193-196
• 19 Cotton P B, Lehman G, Vennes J. et al . Endoscopic sphincterotomy complications and their management: an attempt at consensus.  Gastroentest Endosc. 1991;  37 383-393
• 20 Andriulli A, Leandro G, Federici T. et al . Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.  Gastrointest Endosc. 2007;  65 624-632
• 21 Freeman M L, Overby C, Qi D. Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success.  Gastrointest Endosc. 2004;  59 8-14
• 22 Bergman J J, Rauws E A, Fockens P. et al . Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bile duct stones.  Lancet. 1997;  349 1124-1129
• 23 De Weerth A, Seitz U, Zhong Y. et al . Primary precutting versus conventional over-the-wire sphincterotomy for bile duct access: a prospective randomized study.  Endoscopy. 2006;  38 1235-1240
• 24 Devière J, Le Moine O, Van Laetem J L. et al . Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography.  Gastroenterology. 2001;  120 498-505
• 25 Dumot J A, Conwell D L, Zuccaro G. et al . A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis.  Am J Gastroenterol. 2001;  96 2098-2102
• 26 Kapetanos D, Kohozidis G, Christodoulou D. et al . A randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitis.  Gastrointest Endosc. 2007;  66 513-518